{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:02:34Z","timestamp":1790704954684,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rift Valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that causes severe outbreaks among wild and domesticated ruminants, of which sheep are the most susceptible. Outbreaks are characterised by high mortality rates among new-born lambs and abortion storms, in which all pregnant ewes in a flock may abort their foetuses. In endemic areas, Rift Valley fever (RVF) can be controlled by vaccination with either inactivated or live-attenuated vaccines. Inactivated vaccines are safe for animals during all physiological stages, including pregnancy. However, optimal efficacy of these vaccines depends on multiple vaccinations and yearly re-vaccination. Live-attenuated vaccines are generally highly efficacious after a single vaccination, but currently available live-attenuated vaccines may transmit to the ovine foetus, resulting in stillbirths, congenital malformations or abortion. We have previously reported the development of a novel live-attenuated RVFV vaccine, named RVFV-4s. This vaccine virus was created by splitting the M genome segment and deleting the major virulence determinant NSs, and was shown to be safe even for the most susceptible species, including pregnant ewes. The demonstrated efficacy and safety profile suggests that RVFV-4s holds promise for veterinary and human application. The RVFV-4s vaccine for veterinary application, here referred to as vRVFV-4s, was shown to provide complete protection after a single vaccination of lambs, goats and cattle. In this work, we evaluated the efficacy of the vRVFV-4s vaccine in pregnant ewes. Anticipating on the extremely high susceptibility of pregnant ewes for RVFV, both a single vaccination and double vaccination were evaluated in two independent experiments. The combined results suggest that a single vaccination with vRVFV-4s is sufficient to protect pregnant ewes and to prevent transmission to the ovine foetus.<\/jats:p>","DOI":"10.1038\/s41541-020-00271-7","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T11:13:01Z","timestamp":1610104381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A single vaccination with four-segmented Rift Valley fever virus prevents vertical transmission of the wild-type virus in pregnant ewes"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9790-2438","authenticated-orcid":false,"given":"Paul J.","family":"Wichgers Schreur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Oymans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jet","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"van de Water","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Koll\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dehon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1l","family":"So\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"P\u00e9nzes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucien","family":"van Keulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0329-0176","authenticated-orcid":false,"given":"Jeroen","family":"Kortekaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"271_CR1","doi-asserted-by":"publisher","first-page":"13335","DOI":"10.1128\/JVI.01238-07","volume":"81","author":"S Won","year":"2007","unstructured":"Won, S., Ikegami, T., Peters, C. J. & Makino, S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81, 13335\u201313345 (2007).","journal-title":"J. Virol."},{"key":"271_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087385","volume":"9","author":"HM Weingartl","year":"2014","unstructured":"Weingartl, H. M. et al. Rift Valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6\/36 cells. PLoS ONE 9, e87385 (2014).","journal-title":"PLoS ONE"},{"key":"271_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002670","volume":"8","author":"RC Kading","year":"2014","unstructured":"Kading, R. C. et al. Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. PLoS Negl. Trop. Dis. 8, e2670 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"271_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12985-016-0573-8","volume":"13","author":"HJ Ly","year":"2016","unstructured":"Ly, H. J. & Ikegami, T. Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins. Virol. J. 13, 118 (2016).","journal-title":"Virol. J."},{"key":"271_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1099\/jgv.0.001296","volume":"100","author":"D Wright","year":"2019","unstructured":"Wright, D., Kortekaas, J., Bowden, T. A. & Warimwe, G. M. Rift Valley fever: biology and epidemiology. J. Gen. Virol. 100, 1187\u20131199 (2019).","journal-title":"J. Gen. Virol."},{"key":"271_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","volume":"3","author":"T Ikegami","year":"2011","unstructured":"Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. Viruses 3, 493\u2013519 (2011).","journal-title":"Viruses"},{"key":"271_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007898","volume":"14","author":"J Oymans","year":"2020","unstructured":"Oymans, J., Wichgers Schreur, P. J., van Keulen, L., Kant, J. & Kortekaas, J. Rift Valley fever virus targets the maternal-foetal interface in ovine and human placentas. PLoS Negl. Trop. Dis. 14, e0007898 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"271_CR8","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1016\/S2214-109X(16)30176-0","volume":"4","author":"M Baudin","year":"2016","unstructured":"Baudin, M. et al. Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study. Lancet Glob. Health 4, e864\u2013e871 (2016).","journal-title":"Lancet Glob. Health"},{"key":"271_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau9812","volume":"4","author":"CM McMillen","year":"2018","unstructured":"McMillen, C. M. et al. Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection. Sci. Adv. 4, eaau9812 (2018).","journal-title":"Sci. Adv."},{"key":"271_CR10","first-page":"1","volume":"30","author":"KC Smithburn","year":"1949","unstructured":"Smithburn, K. C. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br. J. Exp. Pathol. 30, 1\u201316 (1949).","journal-title":"Br. J. Exp. Pathol."},{"key":"271_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/jmv.20624","volume":"78","author":"B Botros","year":"2006","unstructured":"Botros, B. et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J. Med. Virol. 78, 787\u2013791 (2006).","journal-title":"J. Med. Virol."},{"key":"271_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","volume":"53","author":"R Muller","year":"1995","unstructured":"Muller, R. et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 53, 405\u2013411 (1995).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"271_CR13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","volume":"75","author":"M Bouloy","year":"2001","unstructured":"Bouloy, M. et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 75, 1371\u20131377 (2001).","journal-title":"J Virol"},{"key":"271_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004550","volume":"10","author":"B Makoschey","year":"2016","unstructured":"Makoschey, B. et al. Rift Valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths. PLoS Negl. Trop. Dis. 10, e0004550 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"271_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003550","volume":"9","author":"MK Njenga","year":"2015","unstructured":"Njenga, M. K. et al. Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock. PLoS Negl. Trop. Dis. 9, e0003550 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"271_CR16","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1016\/j.vaccine.2011.05.055","volume":"29","author":"B von Teichman","year":"2011","unstructured":"von Teichman, B. et al. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 29, 5771\u20135777 (2011).","journal-title":"Vaccine"},{"key":"271_CR17","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","volume":"28","author":"B Dungu","year":"2010","unstructured":"Dungu, B. et al. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 28, 4581\u20134587 (2010).","journal-title":"Vaccine"},{"key":"271_CR18","doi-asserted-by":"publisher","first-page":"10883","DOI":"10.1128\/JVI.00961-14","volume":"88","author":"PJ Wichgers Schreur","year":"2014","unstructured":"Wichgers Schreur, P. J., Oreshkova, N., Moormann, R. J. & Kortekaas, J. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging. J. Virol. 88, 10883\u201310893 (2014).","journal-title":"J. Virol."},{"key":"271_CR19","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.vaccine.2017.04.024","volume":"35","author":"PJ Wichgers Schreur","year":"2017","unstructured":"Wichgers Schreur, P. J., van Keulen, L., Kant, J. & Kortekaas, J. Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy. Vaccine 35, 3123\u20133128 (2017).","journal-title":"Vaccine"},{"key":"271_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00212-4","volume":"5","author":"PJ Wichgers Schreur","year":"2020","unstructured":"Wichgers Schreur, P. J. et al. Safety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattle. NPJ Vaccines 5, 65 (2020).","journal-title":"NPJ Vaccines"},{"key":"271_CR21","doi-asserted-by":"publisher","first-page":"12622","DOI":"10.1128\/JVI.00841-11","volume":"85","author":"J Kortekaas","year":"2011","unstructured":"Kortekaas, J. et al. Creation of a nonspreading Rift Valley fever virus. J. Virol. 85, 12622\u201312630 (2011).","journal-title":"J. Virol."},{"key":"271_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0138-0","volume":"4","author":"A Stedman","year":"2019","unstructured":"Stedman, A. et al. Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. NPJ Vaccines 4, 44 (2019).","journal-title":"NPJ Vaccines"},{"key":"271_CR23","first-page":"351","volume":"15","author":"I Vatnick","year":"1991","unstructured":"Vatnick, I., Schoknecht, P. A., Darrigrand, R. & Bell, A. W. Growth and metabolism of the placenta after unilateral fetectomy in twin pregnant ewes. J. Dev. Physiol. 15, 351\u2013356 (1991).","journal-title":"J. Dev. Physiol."},{"key":"271_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0143-4004(98)90008-X","volume":"19","author":"L Penninga","year":"1998","unstructured":"Penninga, L. & Longo, L. D. Ovine placentome morphology: effect of high altitude, long-term hypoxia. Placenta 19, 187\u2013193 (1998).","journal-title":"Placenta"},{"key":"271_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1095\/biolreprod.105.046342","volume":"74","author":"JW Ward","year":"2006","unstructured":"Ward, J. W., Forhead, A. J., Wooding, F. B. & Fowden, A. L. Functional significance and cortisol dependence of the gross morphology of ovine placentomes during late gestation. Biol. Reprod. 74, 137\u2013145 (2006).","journal-title":"Biol. Reprod."},{"key":"271_CR26","doi-asserted-by":"crossref","unstructured":"Miller, M. A. & Zachary, J. F. Pathologic Basis of Veterinary Disease. (ed. Zachary J. F.), Vol. 2\u201343.e19 (Elsevier Inc., 2017).","DOI":"10.1016\/B978-0-323-35775-3.00001-1"},{"key":"271_CR27","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","volume":"28","author":"SM de Boer","year":"2010","unstructured":"de Boer, S. M. et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28, 2330\u20132339 (2010).","journal-title":"Vaccine"},{"key":"271_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.joca.2012.02.010","volume":"20","author":"C Kilkenny","year":"2012","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage 20, 256\u2013260 (2012).","journal-title":"Osteoarthritis Cartilage"},{"key":"271_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jviromet.2017.06.001","volume":"248","author":"PJ Wichgers Schreur","year":"2017","unstructured":"Wichgers Schreur, P. J., Paweska, J. T., Kant, J. & Kortekaas, J. A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test. J. Virol. Methods 248, 26\u201330 (2017).","journal-title":"J. Virol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00271-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00271-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00271-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:26:40Z","timestamp":1670023600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00271-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["271"],"URL":"https:\/\/doi.org\/10.1038\/s41541-020-00271-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.J.W.S. and J.Ko. are inventors of WIPO Patent Application WO\/2014\/189372 \u201cBunyaviruses with segmented glycoprotein genes and methods for generating these viruses\u201d, owned by BunyaVax B.V. J.Ko. and P.J.W.S. are Chief Scientific Officer and Chief Operations Officer, respectively, of BunyaVax. P.S., Y.D., A.K. and Z.P. are employees of Ceva Animal Health. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}